# AQP4‐ab‐Positive Neuromyelitis Optica Spectrum Disorder Increases the Risk of Hydrocephalus: A Bidirectional Mendelian Randomization Study

**Authors:** Weitao Zhong, Weisong Li, Qiwei Huang, Zelin Li, Qiang Wang, Wangming Zhang

PMC · DOI: 10.1002/brb3.70804 · Brain and Behavior · 2025-10-15

## TL;DR

This study finds that a specific type of autoimmune disorder increases the risk of hydrocephalus using genetic data analysis.

## Contribution

The study uses bidirectional Mendelian randomization to establish a causal link between AQP4-ab-positive NMOSD and hydrocephalus.

## Key findings

- Genetically predicted AQP4-ab-positive NMOSD significantly increases the risk of hydrocephalus.
- Reverse MR analysis found no significant causal effect of hydrocephalus on AQP4-ab-positive NMOSD.
- Sensitivity analyses confirmed the robustness of the findings with no heterogeneity or pleiotropy detected.

## Abstract

Introduction: Some observational studies indicated that AQP4‐ab‐positive neuromyelitis optica spectrum disorder (NMOSD) may predispose to hydrocephalus. However, the causal relationship between NMOSD and hydrocephalus remains elusive. We used bidirectional Mendelian randomization (MR) to examine the causal effect of AQP4‐ab‐positive NMOSD and hydrocephalus.

Methods: The exposure GWAS data used in this study were obtained from the GWAS Catalog, which included 132 AQP4‐ab‐positive patients and 1244 normal controls. The outcome GWAS data for hydrocephalus (N_case = 2455, N_control = 382,198) were obtained from FinnGen R10. We used the inverse‐variance weighted (IVW) method to perform the principal analyses. Then, we used the Cochrane Q‐statistics test to assess the presence of heterogeneity and MR‐Egger‑intercept test to evaluate the pleiotropy for sensitivity analyses. A reverse MR analysis was used to investigate the potential for reverse causation.

Results: In the IVW analysis, we found that genetically predicted AQP4‐ab‐positive NMOSD was significantly associated with the increasing risk of hydrocephalus (OR = 1.05; 95% CI: 1.02–1.08; p = 7.65 × 10−5). In reverse MR analysis, we did not find genetically predicted hydrocephalus significantly associated with AQP4‐ab‐positive NMOSD (p > 0.05). In the sensitivity analysis, both the primary and reverse MR results exhibit no heterogeneity and horizontal pleiotropy.

Discussion: Our results indicate that genetically predicted AQP4‐ab‐positive NMOSD significantly increases the risk of hydrocephalus. The reduced immune activity of AQP4 may play an important role in the pathogenesis of hydrocephalus.

This study employed Mendelian randomization (MR) analysis to investigate the causal relationship between AQP4‐antibody‐positive neuromyelitis optica spectrum disorder (NMOSD) and hydrocephalus. Using genetic variants as instrumental variables, we analyzed data from the GWAS Catalog (N_case = 132, N_control = 1244) for AQP4‐positive NMOSD exposure and FinnGen R10 (N_case = 2455, N_control = 382,198) for hydrocephalus outcomes. The analysis utilized inverse‐variance weighted methods as the primary approach, with sensitivity analyses including reverse MR, the Cochrane Q‐statistics test, and the MR‐Egger intercept to assess the robustness of causal inferences and potential pleiotropy effects.

## Linked entities

- **Proteins:** AQP4 (aquaporin 4)
- **Diseases:** neuromyelitis optica spectrum disorder (MONDO:0019100), hydrocephalus (MONDO:0001150)

## Full-text entities

- **Genes:** AQP4 (aquaporin 4) [NCBI Gene 361] {aka MIWC, MLC4, WCH4, hAQP4}
- **Diseases:** NMOSD (MESH:D009471), Hydrocephalus (MESH:D006849)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12527984/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12527984/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC12527984/full.md

---
Source: https://tomesphere.com/paper/PMC12527984